Seattle Genetics, Takeda announce positive data from Phase 3 trial of Adcetris

Seattle Genetics, Takeda announce positive data from Phase 3 trial of Adcetris Seattle Genetics and Takeda Pharmaceutical announced that patients with Hodgkin lymphoma who received ADCETRIS as consolidation therapy immediately following an autologous stem cell transplantation lived significantly longer without disease progression compared to patients who received placebo. The phase 3 clinical trial, known as AETHERA, compared the use of single agent ADCETRIS to placebo in 329 patients with HL who were at risk of relapse.

http://ift.tt/YFO9KA